Table 1.
Patients' characteristics
| Patient | Gender | Age | LM | Diagnosis | CT/MRI | CSF cell count | CSF cytology | CSF-IC | Light chain on primary |
| 1 | W | 46 | Yes | CLL | LM | 1054 | Lymphocytes | Kappa | Kappa |
| 2 | W | 47 | Yes | LPL | Focal lesions | 25 | Lymphocytes | Kappa | Kappa |
| 3 | M | 64 | Yes | DLCL, Stage IV | N.D. | 109 | Lymphoblasts | N.D. | N.D. |
| 4 | M | 65 | Yes | LPL | LM | 113 | Lymphocytes | N.D. | Kappa |
| 5 | M | 68 | Yes | DLCL, Stage IVE | NEM | 24 | Lymphocytes | Kappa | Kappa |
| 6 | M | 28 | No | PTLPD, Stage IVE | NEM | <10 | N.S.C. | N.D. | N.D. |
| 7 | M | 29 | No | FL Stage Ie (tonsil) | NEM | <10 | N.S.C. | N.D. | N.D. |
| 8 | M | 37 | No | DLCL Stage II | NEM | <10 | N.S.C. | N.D. | N.D. |
| 9 | M | 46 | No | DLCL, Stage IVE | NEM | 23 | N.S.C. | N.D. | Kappa |
| 10 | W | 50 | No | DLCL, Stage III | Focal Lesion | <10 | N.S.C. | N.D. | N.D. |
| 11 | M | 63 | No | M. Hodgkin, Stage IV | N.D. | <10 | N.S.C. | N.D. | No |
| 12 | W | 66 | No | Intracerebral PTLPD | Focal Lesion | 119 | Lymphocytes | CD 3 | N.D. |
| 13 | W | 66 | No | Lymphoblastic T-NHL | N.D. | <10 | N.S.C. | N.D. | No |
| 14 | M | 73 | No | Ocular Lymphoma | NEM | <10 | N.S.C. | N.D. | N.D. |
| 15 | M | 77 | No | CLL, Parkinson's Disease | NEM | <10 | N.S.C. | N.D. | No |
| 16 | M | 79 | No | M. Hodgkin, Stage III | NEM | 27 | N.S.C. | N.D. | No |
| 17 | M | 82 | No | DLCL St. IE (Spinal Cord) | N.D. | 90 | Lymphocytes | CD3 | N.D. |
LM – lymphomatous meningitis; CT – computed tomography; MRI – magnetic resonance imaging; CSF – cerebrospinal fluid; IC – immuncytochemistry, CLL – chronic lymphocytic leukaemia; DLCL – diffuse large cell lymphoma; LPL – lymphoplasmocytic lymphoma, PTLPD – post-transplantation lymphoproliferative disorder; FL – follicular lymphoma; T-NHL – Non-Hodgkin's Lymphoma of T-cell origin.
NEM – no evidence of lymphomatous meningitis; N.S.C. – no suspicious cells; N.D. – not done; EP-4 – epithelial cell surface marker